Reports Q3 revenue $2.79B, consensus $890K. As of September 30, POINT had approximately $399.0M in cash, cash equivalents, and investments, which is anticipated to fund operations into 2026. “The founding mission of our company is to accelerate the discovery, development and global access to radiopharmaceuticals,” said CEO Joe McCann. “I view Lilly’s agreement to acquire POINT as validation of the uniqueness of our team, infrastructure and pipeline. Together, we can become a global radiopharmaceutical leader, executing on our mission and transforming lives touched by cancer.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PNT:
- Largest borrow rate increases among liquid names
- POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
- Eli Lilly extends tender offer to acquire Point Biopharma for $12.50 per share
- PNT Earnings this Week: How Will it Perform?